Warning letter
Angiplast Private Limited: warning letter of May 14, 2020
FDA warning letter 607616 · Center for Devices and Radiological Health
Key facts
| Reference number | 607616 |
|---|---|
| Company | Angiplast Private Limited |
| Subject | CGMP/QSR/Medical Devices/Adulterated |
| Issue date | May 14, 2020 |
| Posted date | May 26, 2020 |
| Issuing office | Center for Devices and Radiological Health |
| Product type | Devices |
| CFR sections cited | 820 |
| Inspection city | Daskroi |
| Inspection start date | Jan 27, 2020 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: